A Novel HLA-B18 Restricted CD8+ T Cell Epitope Is Efficiently Cross-Presented by Dendritic Cells from Soluble Tumor Antigen

NY-ESO-1 has been a major target of many immunotherapy trials because it is expressed by various cancers and is highly immunogenic. In this study, we have identified a novel HLA-B*1801-restricted CD8(+) T cell epitope, NY-ESO-1(88–96) (LEFYLAMPF) and compared its direct- and cross-presentation to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Rona Y., Mifsud, Nicole A., Xiao, Kun, Chan, Kok-Fei, Oveissi, Sara, Jackson, Heather M., Dimopoulos, Nektaria, Guillaume, Philippe, Knights, Ashley J., Lowen, Tamara, Robson, Neil C., Russell, Sarah E., Scotet, Emmanuel, Davis, Ian D., Maraskovsky, Eugene, Cebon, Jonathan, Luescher, Immanuel F., Chen, Weisan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435279/
https://www.ncbi.nlm.nih.gov/pubmed/22970293
http://dx.doi.org/10.1371/journal.pone.0044707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435279/
https://www.ncbi.nlm.nih.gov/pubmed/22970293
http://dx.doi.org/10.1371/journal.pone.0044707

Ejemplares similares